Regulations
Zolgensma data: ‘Heavy-handiness’ of FDA a warning to industry, not just Novartis
RegulationsZolgensma data: ‘Heavy-handiness’ of FDA a warning to industry, not just NovartisZolgensma data: ‘Heavy-handiness’ of FDA a warning to industry, not just Novartis
The US FDA may have made an example of Novartis in the way it handled Zolgensma data manipulation, says the Alliance for Regenerative Medicine.